

IN THE CLAIMS:

Cancel claims 11-17, 26, 27, 34 and 35.

Amend claim 18 as follows:

A2  
Sub C4

18. (Amended) A composition comprising an antibody which specifically reacts with [a protein of claim 11] an isolated IL-13bc protein comprising an amino acid sequence selected from the group consisting of

- the amino acid sequence of SEQ ID NO:2;
- the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334;
- the amino acid sequence of SEQ ID NO:2 from amino acids 357 to 383;
- the amino acid sequence of SEQ ID NO:4;
- the amino acid sequence of SEQ ID NO:4 from amino acids 26 to 341; and
- the amino acid sequence of SEQ ID NO:4 from amino acids 363 to 380.

Add new claims 50-57.

A3  
Sub C6  
RUE 1.126

3850. An inhibitor of IL-13 binding to the IL-13 receptor, said inhibitor being identified by a method comprising the steps of:

- combining a protein selected from the group consisting of
- the amino acid sequence of SEQ ID NO:2;
- the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334;
- the amino acid sequence of SEQ ID NO:2 from amino acids 357 to 383;
- the amino acid sequence of SEQ ID NO:4;
- the amino acid sequence of SEQ ID NO:4 from amino acids 26 to 341; and
- the amino acid sequence of SEQ ID NO:4 from amino acids 363 to 380,

with IL-13 or a fragment thereof, said combination forming a first binding mixture;

measuring the amount of binding between the protein and the IL-13 or fragment in the first binding mixture;

combining a compound with the protein and the IL-13 or fragment to form a second binding mixture;

measuring the amount of binding in the second binding mixture; and  
comparing the amount of binding in the first binding mixture with the amount of  
binding in the second binding mixture;

wherein the compound is capable of inhibiting IL-13 binding to the IL-13 receptor  
when a decrease in the amount of binding of the second binding mixture occurs.

39  
31. A pharmaceutical composition comprising the inhibitor of claim 38 and a  
pharmaceutically acceptable carrier.

40  
32. A method of inhibiting binding of IL-13 to the IL-13 receptor in a mammalian  
subject, said method comprising administering a therapeutically effective amount of a  
composition of claim 31. 39

41  
33. A method of inhibiting binding IL-13 to the IL-13 receptor in a mammalian  
subject, said method comprising administering a therapeutically effective amount of a  
composition comprising an antibody which specifically reacts with an isolated IL-13bc protein  
comprising an amino acid sequence selected from the group consisting of

the amino acid sequence of SEQ ID NO:2;  
the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334;  
the amino acid sequence of SEQ ID NO:2 from amino acids 357 to 383;  
the amino acid sequence of SEQ ID NO:4;  
the amino acid sequence of SEQ ID NO:4 from amino acids 26 to 341; and  
the amino acid sequence of SEQ ID NO:4 from amino acids 363 to 380.

42  
34. A method for potentiating IL-13 activity, said method comprising combining a  
protein having IL-13 activity with an isolated IL-13bc protein comprising an amino acid  
sequence selected from the group consisting of

the amino acid sequence of SEQ ID NO:2;  
the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334;  
the amino acid sequence of SEQ ID NO:2 from amino acids 357 to 383;  
the amino acid sequence of SEQ ID NO:4;